Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of Second Innovative Formulation of 5-MeO-DMT

Beckley Psytech has announced that the first healthy volunteers have been dosed in a Phase I clinical trial exploring the safety and pharmacokinetics of BPL-003, Beckley Psytech’s second innovative formulation of 5-MeO-DMT.

Category Press Release
Published in Businewsswire

Companies Featured

Beckley Psytech
Beckley Psytech is working on getting 5-MeO-DMT to market as the first of a variety of psychedelic medicines.